Cost-Utility Analysis of Certoluzimab Pegol versus Alternative Tumor Necrosis Factor-Inhibitors, for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain

Autores: Villoro R, Hidalgo A, Ferro B, Talavera P
Fecha: Noviembre 2011

pdf